Pharmapurerx Menthotral

Lidocaine, Menthol


Puretek Corporation
Human Otc Drug
NDC 59088-587
Pharmapurerx Menthotral also known as Lidocaine, Menthol is a human otc drug labeled by 'Puretek Corporation'. National Drug Code (NDC) number for Pharmapurerx Menthotral is 59088-587. This drug is available in dosage form of Cream. The names of the active, medicinal ingredients in Pharmapurerx Menthotral drug includes Lidocaine Hydrochloride Anhydrous - 38.8 mg/mL Menthol - 30 mg/mL . The currest status of Pharmapurerx Menthotral drug is Active.

Drug Information:

Drug NDC: 59088-587
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Pharmapurerx Menthotral
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Lidocaine, Menthol
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Puretek Corporation
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Cream
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:LIDOCAINE HYDROCHLORIDE ANHYDROUS - 38.8 mg/mL
MENTHOL - 30 mg/mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED DRUG OTHER
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 03 Aug, 2017
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 09 May, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:PureTek Corporation
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UPC:0359088587164
UPC stands for Universal Product Code.
UNII:EC2CNF7XFP
L7T10EIP3A
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:Amide Local Anesthetic [EPC]
Amides [CS]
Antiarrhythmic [EPC]
Local Anesthesia [PE]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
59088-587-16237 mL in 1 BOTTLE, PUMP (59088-587-16)03 Aug, 2017N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purposes topical anesthetic (lidocaine 3.88%) topical analgesic (menthol 3%)

Product Elements:

Pharmapurerx menthotral lidocaine, menthol lidocaine hydrochloride anhydrous lidocaine menthol menthol aminomethylpropanol carbomer homopolymer type c (allyl pentaerythritol crosslinked) polyoxyl 20 cetostearyl ether cetyl ethylhexanoate cetyl phosphate diisobutyl adipate edetate disodium glycerin glyceryl stearate se phenoxyethanol water stearic acid

Indications and Usage:

Uses for the temporary relief of minor pain, itching and irritation due to / associated with ■ simple backache ■ arthritis ■ sprains ■ muscle strains ■ bruises ■ minor cuts/scrapes ■ minor burns/sunburn ■ insect bites

Warnings:

Warnings for external use only do not use ■ if allergic to lidocaine or any other local anesthetics ■ over a large skin area ■ on deep puncture wounds ■ on infections ■ on raw surfaces or blistered areas when using this product ■ do not get into eyes ■ do not use in large quantities ■ do not bandage or apply heat to treated areas ■ wash hands immediately after using stop use and ask a doctor if ■ condition worsens ■ symptoms last more than 7 days or clear up and occur again within a few days if pregnant or breast-feeding, ask a health professional before use. keep out of reach of children. if swallowed, get medical help or contact a poison control center right away.

Do Not Use:

Warnings for external use only do not use ■ if allergic to lidocaine or any other local anesthetics ■ over a large skin area ■ on deep puncture wounds ■ on infections ■ on raw surfaces or blistered areas when using this product ■ do not get into eyes ■ do not use in large quantities ■ do not bandage or apply heat to treated areas ■ wash hands immediately after using stop use and ask a doctor if ■ condition worsens ■ symptoms last more than 7 days or clear up and occur again within a few days if pregnant or breast-feeding, ask a health professional before use. keep out of reach of children. if swallowed, get medical help or contact a poison control center right away.

When Using:

When using this product ■ do not get into eyes ■ do not use in large quantities ■ do not bandage or apply heat to treated areas ■ wash hands immediately after using

Dosage and Administration:

Directions ■ adults and children over 12 years of age: apply a thin layer to the affected area up to 3 to 4 times a day ■ children 12 years of age or younger: consult a doctor

Stop Use:

Stop use and ask a doctor if ■ condition worsens ■ symptoms last more than 7 days or clear up and occur again within a few days

Package Label Principal Display Panel:

Pharmapurerx ® menthotral™ cream (lidocaine 3.88% / menthol 3%) topical use only manufactured in the usa by: puretek corporation san fernando, ca 91340 877-921-7873 image description


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.